USD 511.3 billion
Report ID:
SQMIG35H2127 |
Region:
Global |
Published Date: July, 2024
Pages:
219
|Tables:
155
|Figures:
78
Biologics Market size was valued at USD 511.3 billion in 2023 and is poised to grow from USD 567.54 billion in 2024 to USD 1307.92 billion by 2032, growing at a CAGR of 11.0% during the forecast period (2025-2032).
The global biologics market has performed well with significant growth and development in recent years. Biologic drugs also known as biologics, they are pharmaceutical compounds derived from living organisms such as humans, animals and microorganisms. These compounds are biologically stable and synthesized by biotechnology, often involving recombinant DNA technology. The biologics market offers innovative and effective therapies for various diseases and medical conditions. Biomedicine has revolutionized treatment, offering targeted and personalized approaches to patients. It is widely used in treating chronic diseases like cancer, immune system and infectious diseases. The market aims to develop and distribute biopharmaceuticals that improve disease control and improve quality of life. The growth factors of the biopharmaceutical market are the increasing prevalence of chronic diseases across the globe. The increasing incidence of diseases such as cancer, diabetes and arthritis has increased the demand for biopharmaceuticals. The importance of preservation and transfer of biomass is sensitive to temperature and environmental factors. Maintaining organic integrity and consistency throughout the supply chain can be complex and expensive.
US Biologics Market is poised to grow at sustainable CAGR for the next forecast year
Market snapshot - 2025-2032
Global Market Size
USD 511.3 billion
Largest Segment
Monoclonal Antibodies
Fastest Growth
Antisense and RNAi Therapeutics
Growth Rate
11.0% CAGR
To get more reports on the above market click here to Buy The Report
Global Biologics Market is segmented by Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel and region. Based on Type, the market is segmented into Tumor Necrosis Factor (TNF) Inhibitor, T-cell Inhibitor, Selective Co-stimulation Modulators, Interleukin-6 (IL-6) or Interleukin-17 Blocker, Interleukin-1 (IL-1) Blocker and B-cell Inhibitor. Based on Drug Class, the market is segmented into Monoclonal Antibody, Recombinant Insulin, Vaccine, Blood Factor, Human Growth Hormone, Erythropoietin, Fusion Protein, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Gene Therapy, Peptide, Botulinum Toxin and Others. Based on Therapeutic Application, the market is segmented into Oncology, Autoimmune/Immunologic Diseases, Metabolic Disorders, Ophthalmic Diseases, Respiratory Disorders, Inflammatory Bowel Diseases (IBDs), Neurological Disorders, Cardiovascular Diseases (CVDs), Musculoskeletal Disorders (MSDs), Infectious Diseases and Others. Based on Source, the market is segmented into Microbial, Mammalian and Others. Based on Manufacturing, the market is segmented into Outsourced and In-House. Based on Drug Type, the market is segmented into Branded Drugs and Generic Drugs. Based on Mode of Purchase, the market is segmented into Prescription Drugs and Over-The-Counter (OTC) Drugs. Based on Dosage Form, the market is segmented into Injection, Tablets and Others. Based on Route of Administration, the market is segmented into Parenteral, Oral and Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Analysis by Product
The monoclonal antibodies segment accounted for 66.42% share in 2023 as this drug class was widely used in various therapeutic areas. MAbs can target unhealthy cells without harming healthy cells. So far, monoclonal antibodies have emerged as the main class of approved antibodies. In 2021, the U.S. FDA reached a milestone by approving its 100th monoclonal antibody product. This is due to their lower risk of immune activation compared to chimeric antibodies.
The antisense and RNAi therapeutics segment is anticipated to expand at a CAGR of 20.6% for the duration of the forecast duration. These biological properties facilitate genes, leading to the development and approval of many gene-silencing drugs for genetic illnesses. For example, In June 2022 Alnylam Pharmaceuticals, Inc. received FDA approval for its RNAi therapy AMVUTTRA for the treatment of Polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.
The oncology segment dominated the biologics industry with a 28.40% share in 2022. According to the American Cancer Society, about 1.92 million new cancers will be the second leading cause of cancer in the US. in 2022. The advent of biologics, particularly monoclonal antibodies and immunotherapy therapies has dramatically increased cancer treatment by improving survival rates.
The hematology disorders segment is expected to expand at the fastest CAGR of 11.7% during the forecast period. Approval of gene therapies for rare blood disorders such as the hemophilia is expected to be a key driver for market growth. For example, in November 2022, the U.S. The FDA approved CSL Behring Hemgenix for the treatment of adults with hemophilia B. In addition, in August 2022, BioMarin ROCTAVIAN was also approved in Europe for the treatment of hemophilia A.
To get detailed analysis on other segments, Request For Free Sample Report
In 2022, North America held the most important sales proportion of 44.37% in the biologics marketplace. This may be attributed to several elements. Additionally, North America is domestic to several leading biopharmaceutical corporations, contributing to the growth of the marketplace. Favorable reimbursement guidelines and sizeable investments in studies and development in addition help the market's expansion.
The Asia Pacific place is projected to grow at a CAGR of 11.0% during the forecast length. The region is experiencing a growing burden of sicknesses like most cancers, diabetes, and cardiovascular diseases, coupled with a boom in the geriatric population. This has brought about an improved demand for biology in the place. Market leaders inside the industry are actively specializing in assembly this demand and making enormous investments in the development of superior biologic merchandise.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increased Chronic Diseases
Advances in Biotechnology
High Production Costs
Regulatory Approval Challenges
Request Free Customization of this report to help us to meet your business objectives.
The global biologics market is characterized via extreme opposition amongst key market gamers striving to hold their market position and benefit from a competitive side. The marketplace is dominated with the resource of essential pharmaceutical agencies, biotechnology companies, and agreement production agencies (CMOs) specializing in biologic drug improvement and production. Companies which include Biogen, Genentech, and Gilead Sciences are interested in growing modern-day biologics and investing in studies to expand medical understanding and recuperation options. Biogen's more than one sclerosis drug, Tecfidera, and Gilead Sciences' antiviral drug, Remdesivir, have made vast contributions to their market presence.
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected by smeans of Primary Exploratory Research backed by robust Secondary Desk research.
According to SkyQuest analysis, the global biologics market is anticipated to enjoy significant boom during the forecast period from 2024 to 2031. They provide targeted and personalised remedies for various sicknesses, which includes most cancers, autoimmune problems, and uncommon genetic conditions. The marketplace evaluation of the biologics industry entails studying different factors that effect its boom and performance. These factors encompass marketplace size, sales developments, marketplace proportion, and competitive panorama. Market analysis additionally includes assessing the call for and supply dynamics, pricing tendencies, regulatory environment, and technological advancements in the enterprise.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 511.3 billion |
Market size value in 2032 | USD 1307.92 billion |
Growth Rate | 11.0% |
Base year | 2024 |
Forecast period | 2025-2032 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Biologics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Biologics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Biologics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Biologics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Biologics Market size was valued at USD 510.05 Billion in 2023 and is poised to grow from USD 563.1 Billion in 2024 to USD 12282.61 Billion by 2032, growing at a CAGR of 10.40% during the forecast period (2025-2032).
The global biologics market is characterized via extreme opposition amongst key market gamers striving to hold their market position and benefit from a competitive side. The marketplace is dominated with the resource of essential pharmaceutical agencies, biotechnology companies, and agreement production agencies (CMOs) specializing in biologic drug improvement and production. Companies which include Biogen, Genentech, and Gilead Sciences are interested in growing modern-day biologics and investing in studies to expand medical understanding and recuperation options. Biogen's more than one sclerosis drug, Tecfidera, and Gilead Sciences' antiviral drug, Remdesivir, have made vast contributions to their market presence. 'Roche (Switzerland)', 'Johnson & Johnson (US)', 'AbbVie (US)', 'Amgen (US)', 'Novartis (Switzerland)', 'Pfizer (US)', 'Merck & Co. (US)', 'AstraZeneca (UK)', 'Bristol Myers Squibb (US)', 'Sanofi (France)', 'Eli Lilly and Company (US)', 'Gilead Sciences (US)', 'Biogen (US)', 'Celgene (US)', 'Novo Nordisk (Denmark)', 'Takeda Pharmaceutical Company (Japan)', 'Bayer (Germany)', 'GlaxoSmithKline (UK)', 'Boehringer Ingelheim (Germany)', 'Vertex Pharmaceuticals (US)'
The increasing incidence of chronic conditions such as cancer, diabetes and autoimmune diseases has led to a demand for advanced biological therapies. These therapies use targeted therapy built and effective without conventional chemicals, boosting market growth.
The trend towards personalized medicine is dramatically changing the biological market. Personalized biological therapies tailored to individual genetics and disease characteristics will provide effective and targeted treatment. This trend is driving innovation in biological sciences and expanding their applications in medicine.
In 2022, North America held the most important sales proportion of 44.37% in the biologics marketplace. This may be attributed to several elements. Additionally, North America is domestic to several leading biopharmaceutical corporations, contributing to the growth of the marketplace. Favorable reimbursement guidelines and sizeable investments in studies and development in addition help the market's expansion.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
Report ID: SQMIG35H2127
[email protected]
USA +1 351-333-4748